相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies A retrospective analysis of the LifeLink database
Jennie H. Best et al.
DIABETES CARE (2011)
Endothelin-1 overexpression restores diastolic function in eNOS knockout mice
Nicolas Vignon-Zellweger et al.
JOURNAL OF HYPERTENSION (2011)
Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus
Xiaoxiang Yan et al.
CARDIOVASCULAR DIABETOLOGY (2010)
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
A. J. Scheen
DIABETES OBESITY & METABOLISM (2010)
The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans
Stefan Blech et al.
DRUG METABOLISM AND DISPOSITION (2010)
GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats
Hui-Chun Ku et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2010)
Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
David J. Grieve et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Cystatin C for early detection of renal impairment in diabetes
D. Willems et al.
CLINICAL BIOCHEMISTRY (2009)
Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients
T. Heise et al.
DIABETES OBESITY & METABOLISM (2009)
Spironolactone Attenuates Experimental Uremic Cardiomyopathy by Antagonizing Marinobufagenin
Jiang Tian et al.
HYPERTENSION (2009)
BNP-Guided vs Symptom-Guided Heart Failure Therapy The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial
Matthias Pfisterer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats
Yasushi Kirino et al.
JOURNAL OF ENDOCRINOLOGY (2009)
Vascular Calcification: The Killer of Patients with Chronic Kidney Disease
Masahide Mizobuchi et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart
Alvilde Ossum et al.
PHARMACOLOGICAL RESEARCH (2009)
Cystatin C improves the diagnosis and stratification of chronic kidney disease, and the estimation of glomerular filtration rate in diabetes
V. Rigalleau et al.
DIABETES & METABOLISM (2008)
Low-dose growth hormone is cardioprotective in uremia
Ralph Rabkin et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure
P. Kalk et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis
Renee E. Amori et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Cystatin C and estimates of renal function: Searching for a better measure of kidney function in diabetic patients
Laura Pucci et al.
CLINICAL CHEMISTRY (2007)
Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation
Guido Boerrigter et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2007)
NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy
Philipp Kalk et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Chronic kidney disease and mortality risk: A systematic review
Marcello Tonelli et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers
AJ Bergman et al.
CLINICAL THERAPEUTICS (2006)
Identification of target genes of the transcription factor HNF1β and HNF1α in a human embryonic kidney cell line
S Senkel et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION (2005)
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
GA Herman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999
RN Foley et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects
JJ Meier et al.
DIABETES (2004)
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
AS Go et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Gene expression variance based on random sequencing in rat remnant kidney
N Horiba et al.
KIDNEY INTERNATIONAL (2004)
TIMP-1 - A marker of left ventricular diastolic dysfunction and fibrosis in hypertension
MM Lindsay et al.
HYPERTENSION (2002)
分享论文
